Literature DB >> 15811492

Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.

Michael Eaddy1, Amy Grogg, Julie Locklear.   

Abstract

BACKGROUND: Partial compliance with mental health medications has been associated with an increased risk of clinical worsening, relapse, and repeat hospitalization.
OBJECTIVE: The purpose of this study was to evaluate the effect of partial compliance of patients (diagnosed as having schizophrenia or bipolar disorder) with prescribed oral atypical and conventional antipsychotic agents and the corresponding impact on resource utilization.
METHODS: Patients receiving antipsychotic agents ina large Southeastern Medicaid program were grouped according to their level of compliance. Compliance was measured by the continuous, multiple interval medications available methodology. Patients were deemed partially compliant if compliance was <80%, compliant if compliance was 80% to 125%, and overly compliant if compliance was >125%. Medical costs were modeled as a function of compliance while controlling for background covariates. Logistic regression was used to model the probability of specific resource utilization.
RESULTS: A total of 7864 patients were included in this analysis. After controlling for background covariates, partially compliant patients were 49.0% (95% CI, 29.2%-71.7%) more likely than compliant patients to have an inpatient hospitalization and incurred 54.5% (P < 0.001) higher inpatient charges. Partially compliant patients were also 64% (P < 0.01) more likely than compliant patients to switch or augment therapy.
CONCLUSION: Partial compliance was associated with an increased risk of hospitalization and switching or augmentation of therapy when compared with being compliant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15811492     DOI: 10.1016/j.clinthera.2005.02.003

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  24 in total

1.  Psychopharmacological treatment status in outpatients with bipolar disorder: a clinical survey in Germany.

Authors:  Arnim Quante; Sara Zeugmann; Francesca Regen; Annette Engelhardt; Ion-George Anghelescu
Journal:  Psychiatry Investig       Date:  2010-07-09       Impact factor: 2.505

2.  Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US.

Authors:  John Robst
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

Review 3.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

4.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

5.  Religious beliefs in schizophrenia: their relevance for adherence to treatment.

Authors:  L Borras; S Mohr; P-Y Brandt; C Gilliéron; A Eytan; P Huguelet
Journal:  Schizophr Bull       Date:  2007-01-09       Impact factor: 9.306

6.  The predictive validity of subjective adherence measures in patients with schizophrenia.

Authors:  Martijn J Kikkert; Maarten W J Koeter; Jack J M Dekker; Lorenzo Burti; Debbie Robson; Bernd Puschner; Aart H Schene
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

Review 7.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

8.  Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

Authors:  Kyoko Higashi; Goran Medic; Kavi J Littlewood; Teresa Diez; Ola Granström; Marc De Hert
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

9.  Guideline-concordant antipsychotic use and mortality in schizophrenia.

Authors:  Bernadette A Cullen; Emma E McGinty; Yiyi Zhang; Susan C Dosreis; Donald M Steinwachs; Eliseo Guallar; Gail L Daumit
Journal:  Schizophr Bull       Date:  2012-10-30       Impact factor: 9.306

10.  Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations.

Authors:  Monali Bhosle; Joshua S Benner; Mitch Dekoven; Jeff Shelton
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.